

Ingevity Corp  
Form 8-K  
April 26, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15 (d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 26, 2016**

**INGEVITY CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**001-37586**

**47-4027764**

**(State of other jurisdiction of incorporation or organization)**

**(Commission File Number)**

**(I.R.S. Employer Identification No.)**

**5255 Virginia Avenue  
North Charleston, South Carolina  
(Address of principal executive offices)**

**29406  
(Zip Code)**

**Registrant's telephone number, including area code: 844-643-8489**

**Not Applicable  
(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..Written communications pursuant to Rule 425 under the Securities Act
- ..Soliciting material pursuant to Rule 14a-2 under the Exchange Act
- ..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
- ..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION**

Ingevity Corporation ("Ingevity") preliminary financial results for the quarter ended March 31, 2016 and fiscal year 2016 guidance is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Additionally, attached as Exhibit 99.2 to this Current Report on Form 8-K is Ingevity financial information for the quarterly periods in fiscal years 2015 and 2014.

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**ITEM 7.01 REGULATION FD DISCLOSURE**

In advance of the anticipated spin off of Ingevity from WestRock Company ("WestRock"), which is targeted for May 15, 2016, WestRock has prepared investor materials for use in investor discussions.

The presentation slides are available on Ingevity's website at [www.ingevity.com/investors](http://www.ingevity.com/investors). The presentation slides are being furnished as Exhibit 99.4 to this Current Report on Form 8-K. Additionally, a reconciliation of WestRock's Specialty Chemicals' division adjusted EBITDA to Ingevity's adjusted EBITDA is provided as Exhibit 99.3 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.3 and 99.4, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on our current expectations, beliefs, plans or forecasts and are typically identified by words or phrases such as "may," "will," "could," "should," "would,"

"anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "target," "prospects," "potential" and "forecast," and other words, terms and phrases of similar meaning. Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties. We caution readers that a forward-looking statement is not a guarantee of future performance, and actual results could differ materially from those contained in forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding, among other things, the expected timing of the separation of Ingevity Corporation from WestRock Company. We have made assumptions regarding, among other things, whether and when the spin-off of Ingevity Corporation. Our business is subject to a number of general risks that would affect any such forward-looking statements. These risks and other factors that may impact management's assumptions are more particularly described in our filings with the U.S. Securities and Exchange Commission, including our Form 10 Registration Statement. The information contained in this release speaks as of the date of the release and we do not have or undertake any obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

**Exhibit No. Description of Exhibit**

|      |   |
|------|---|
| 99.1 | Ingevity's preliminary financial results for the quarter ended March 31, 2016 and fiscal year 2016 guidance |
| 99.2 | Ingevity financial information for the quarterly periods in fiscal years 2015 and 2014                      |
| 99.3 | Reconciliation of WestRock Specialty Chemicals division adjusted EBITDA to Ingevity's adjusted EBITDA       |
| 99.4 | Analyst Meeting slide deck presented on April 26, 2016  |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**INGEVITY CORPORATION  
(Registrant)**

By: /s/ JOHN C. FORTSON  
**John C. Fortson**  
**Executive Vice President and Chief Financial Officer**

Date: April 26, 2016

**Exhibit No. Description of Exhibit**

- |      |   |
|------|---|
| 99.1 | Ingevity's preliminary financial results for the quarter ended March 31, 2016 and fiscal year 2016 guidance |
| 99.2 | Ingevity financial information for the quarterly periods in fiscal years 2015 and 2014                      |
| 99.3 | Reconciliation of WestRock Specialty Chemicals division adjusted EBITDA to Ingevity's adjusted EBITDA       |
| 99.4 | Analyst Meeting slide deck presented on April 26, 2016  |